Health

US Regulators Deal Blow to Chinese Biotech With Cancer Drug Rejection

RecentNews.uk

01

US Food and Drug Administration declines approval for Summit lung cancer drug

02

Late-stage clinical trials missed essential overall survival metrics

03

Decision impacts cross-border biotech partnerships and oncology investments

Reader poll

Should regulatory standards for experimental cancer treatments be made more flexible?

Tap below to vote and see what others think.

Read the full story